Steve Cohen Buys 7.3% Of Relmada After Stock Fell 80% Last Week


Point72 goes bottom fishing for one of the year’s biggest losers Steve Cohen’s Point72 Asset Management, L.P. said last week it bought 2.1 million shares, or 7.3%, of Relmada Therapeutics Inc (NASDAQ:RLMD), a biotech stock that recently fell 80% after a bad clinical trial. Relmada’s Stock Tumbles Relmada shares tumbled more than 75% on Thursday […]